Edogestrone Explained

Edogestrone (developmental code name PH-218), or edogesterone, also known as 17α-acetoxy-3,3-ethylenedioxy-6-methylpregn-5-en-20-one, is a steroidal progestin and antiandrogen of the 17α-hydroxyprogesterone group which was synthesized in 1964 but was never marketed.^{[1] [2]} Similarly to the structurally related steroid cyproterone acetate, edogestrone binds directly to the androgen receptor and antagonizes it, displacing androgens like testosterone from the receptor, though not as potently as cyproterone acetate.^[3] The drug has also been found to suppress androgen production, likely via progesterone receptor activation-mediated antigonadotropic activity.^[4]

See also

• Steroidal antiandrogen
• List of progestogens
• List of steroidal antiandrogens
• List of progestogen esters

Notes and References

1. Book: Elks J . The Dictionary of Drugs: Chemical Data: Chemical Data, Structures and Bibliographies. 14 November 2014. Springer. 978-1-4757-2085-3. 478–.
2. Geller J, McCoy K . Biologic and biochemical effects of anti-androgens on rat ventral prostate . Acta Endocrinologica . 75 . 2 . 385–397 . February 1974 . 4406552 . 10.1530/acta.0.0750385 .
3. Book: Spring-Mills E, Hafez ES . Male accessory sex glands: biology and pathology. 1 January 1980. Elsevier/North-Holland Biomedical Press. 500. 9780444801678 .
4. Book: Castro JE . The Treatment of Prostatic Hypertrophy and Neoplasia. 9 March 2013. Springer Science & Business Media. 978-94-015-7190-6. 39–. Geller has also demonstrated significant decreases in plasma or urine testosterone glucuronide levels following the administration of three other anti-androgens. These include Delalutin, Chlormadinone acetate, and PH-218. It would appear that decreased androgen production is a property shared by all anti-androgens to date..